NEW YORK, NY / ACCESSWIRE / October 7, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

LIVE Shareholders Click Here: https://www.zlk.com/pslra-1/live-ventures-incorporated-loss-submission-form?prid=20204&wire=1
KPLT Shareholders Click Here: https://www.zlk.com/pslra-1/katapult-holdings-inc-information-request-form?prid=20204&wire=1
SAVA Shareholders Click Here: https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20204&wire=1

* ADDITIONAL INFORMATION BELOW *

Live Ventures Incorporated (NASDAQ:LIVE)

LIVE Lawsuit on behalf of: investors who purchased December 28, 2016 - August 3, 2021
Lead Plaintiff Deadline : October 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/live-ventures-incorporated-loss-submission-form?prid=20204&wire=1

According to the filed complaint, during the class period, Live Ventures Incorporated made materially false and/or misleading statements and/or failed to disclose that: 1) Live's earnings per share for FY 2016 was actually only $6.33 per share; (2) the Company used an artificially low share count to boost the earnings per share by 40%; (3) Live had overstated pretax income for fiscal 2016 by 20% by including $915,500 of "other income" related to certain amendments that were not negotiated until after the close of the fiscal year; (4) Live's acquisition of ApplianceSmart did not close during first quarter 2017; (5) using December 30, 2017 as the "acquisition date" and recognizing income therefrom did not conform to generally accepted accounting principles; (6) by falsely stating that the acquisition closed during the quarter, Live recognized bargain purchase gain, which enabled the Company to report positive net income in what would otherwise have been an unprofitable quarter; (7) between fiscal 2016 and fiscal 2018, Live's CEO received approximately 94% more in compensation than was disclosed to investors; and (8) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Katapult Holdings, Inc. (NASDAQ:KPLT)

KPLT Lawsuit on behalf of: investors who purchased December 18, 2020 - August 10, 2021
Lead Plaintiff Deadline : October 26, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/katapult-holdings-inc-information-request-form?prid=20204&wire=1

According to the filed complaint, during the class period, Katapult Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Katapult was experiencing declining e-commerce retail sales and consumer spending, (2) despite Katapult's assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential goods and enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers' future buying behavior; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Cassava Sciences, Inc. (NASDAQ:SAVA)

SAVA Lawsuit on behalf of: investors who purchased September 14, 2020 - August 27, 2021
Lead Plaintiff Deadline : October 26, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20204&wire=1

According to the filed complaint, during the class period, Cassava Sciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP